来氟米特联合醋酸泼尼松治疗特发性膜性肾病的疗效观察被引量：5

下载PDF

导出

摘要目的探讨来氟米特联合醋酸泼尼松治疗特发性膜性肾病的临床疗效。方法随机将2017年6月至2018年3月本院收治的60例特发性膜性肾病分到A组(n=30例)和B组(n=30例),A组患者予以醋酸泼尼松联合来氟米特治疗,B组患者予以醋酸泼尼松联合环磷酰胺治疗,两组患者的治疗周期均为6个月,对比分析两组患者的临床疗效及不良反应发生率。结果A组患者总有效率为60.00%(18/30),B组患者总有效率为56.67%(17/30),两组比较,P>0.05。A组不良反应发生率为13.33%(4/30),B组不良反应发生率为40.00%(12/30),两组比较,P<0.05。结论醋酸泼尼松联合来氟米特治疗与醋酸泼尼松联合环磷酰胺治疗特发性膜性肾病的疗效相当,但醋酸泼尼松联合来氟米特治疗的不良反应更少。

作者姜述伟

机构地区丹东市第一医院肾内科

出处《中国医药指南》 2019年第24期128-128,共1页 Guide of China Medicine

关键词特发性膜性肾病醋酸泼尼松环磷酰胺来氟米特

分类号 R692 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献6

1尚顺来,李清刚,陈香美.来氟米特联合甲泼尼龙片治疗特发性膜性肾病的疗效分析[J].解放军医学院学报,2018,39(1):1-4. 被引量：18
2楼红玫.醋酸泼尼松不同方案治疗特发性膜性肾病的效果对照评价[J].中华全科医学,2015,13(6):921-923. 被引量：14
3常雄.他克莫司或来氟米特联合泼尼松治疗特发性膜性肾病的疗效及安全性对比[J].药物评价研究,2016,39(5):825-827. 被引量：12
4刘婷,包蓓艳,李国富,尤晓青,刘苑苹,苏醒.来氟米特联合醋酸泼尼松治疗特发性膜性肾病的效果分析[J].实用医学杂志,2010,26(14):2636-2638. 被引量：11
5王天祺,杨颖达.他克莫司与来氟米特治疗特发性膜性肾病的效果及安全性对比[J].中国当代医药,2018,25(2):138-140. 被引量：10
6严海红,王文龙,程勇军.来氟米特联合醋酸泼尼松治疗特发性膜性肾病的临床有效性探究[J].中国基层医药,2014,21(20):3117-3120. 被引量：9

二级参考文献49

1Li L S,Liu Z H.Epidemiologic data of renal diseases from a single unit in China:analysis based on 13,519 renal biopsies[J].Kidney Int,2004,66(3):920-923.
2Cattran D.Management of membranous nephropathy:when and what for treatment[J].J Am Soc Nephrol,2005,16(5):1188-1194.
3Hansen K E,Cush J,Singhal A,et al.The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis[J].Arthritis Rheum,2004,51(2):228-232.
4Williams J W,Mital D,Chong A,et al.Experiences with leflunomide in solid organ transplantation[J].Transplantation,2002,73(3):358-366.
5Passorini P,Ponticelli C.Corticosteroids,cyclophosphamide,and chiorambucil therapy of membranous nephropathyl[J].Seminars in Nephrology,2003,23(4):355-361.
6Ponticelli C,Altieri P,Scolari F,et al.A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophasphamide in idiopathic membranous nephropathy[J].J Am Soc Nephrol,1998,9(3):444-450.
7du Buf-Vereijken P W,Branten A J.Cytotoxic therapy for membranous nephropathy and renal insufficiency:improved renal survival but high relapse rate[J].Nephrol Dial Transplant,2004,19(5):1142-1148.
8Miller G,Zimmerman R,Radhakrishnan J,et al.Use of Mycophenolate Mofetil in Resistant Membranous Nephropathyl[J].Am J Kidney Dis,2000,36(2):250-256.
9Branten A J,du Buf-Vereijken P W,Vervloet M,et al.Mycophenolate mofetil in idiopathic membranous nephropathy:a clinical trial with comparison to a historic control group treated with cyclophosphamide[J].Am J Kidney Dis,2007,50(2):248-256.
10Goumenos D S,Katopodis K P,Passadakis P,et al.Corticosteroids and ciclosporin A in idiopathic membranous nephropathy:higer remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs[J].Am J Nephrol,2007,27(3):226-231.